Response to H1N1
•Strategic National Stockpile
•Distributed 25% pro rata supply
•Enhanced Surveillance Initiated
•PCR panH1N1 kits for testing
•Development at CDC, EUA at FDA, manufacture at ATCC, and ready to ship in ~ 2.5 weeks
Centers for Disease Control
Centers for Disease Control
Novel Influenza A H1N1 Update
* Disease likely persists through summer in US, possible surge in late August when school returns
* Monitor closely for genetic and antigenic virus changes
* Expected higher attack rate (20-30%) than in spring (6-15%), notably affecting younger individuals
* Vaccine availability possibly mid October, Federal funds for distribution and administration are available
* Healthcare facility support in part from HPP grants
* SNS Antiviral stocks likely to be distributed
* Drifted H3N2 may co-circulate with novel H1N1
Centers for Disease Control
Update on pandemic influenza A(H1N1) activity, United States
• Oseltamivir (Tamiflu) and Zanamivir (Relenza)
• Randomized clinical trials (RCT): Reduced duration of influenza by 1-1.5 days when administered in 48 hours
• Pooled RCT analysis: Reduced lower respiratory tract complications, pneumonia, and hospitalization
• Observational studies*: Oseltamivir reduced mortality among hospitalized adults with lab-confirmed seasonal influenza A virus infections
Centers for Disease Control
CDC Director’s Update Brief novel-2009 H1N1 August 14, 2009
* WHO: Pandemic Phase 6 (11 JUN 2009 1600 EDT)
* Outbreaks in at least one country in > two WHO regions
* USG: Public Health Emergency declared (26 Apr 2009)
* Renewed by HHS Secretary Kathleen Sebelius
* HHS: Downgraded to Phase 1 – Awareness (9 May 2009)
Centers for Disease Control
Joint Public Health – Law Enforcement Investigations: Model Memorandum of Understanding (MOU)
Parties agree that this MOU does not create any private rights of action to the general public that would provide a basis for civil liability. Additionally, the MOU does not constrain the statutory or regulatory legal authority of the FBI to investigate federal crimes or any existing authorities of public health agencies.
Centers for Disease Control
Pandemic Influenza A (H1N1) Virology Update
– Antigenic characteristics
– Transmission characteristics
– Severity of disease
– Antiviral resistance
– Intensity (surge) in US cases
Centers for Disease Control
Update on the epidemiology and clinical features of Novel H1N1
• January 2007 –“Novel influenza A” made a Nationally Notifiable Disease but CSTE –part of pandemic preparedness efforts
• RT-PCR for influenza capabilities developed by public health labs in U.S.
• Increasing numbers of swine influenza infections in humans being detected from improved surveillance
• Increasing efforts at states, CDC, and USDA to investigate human cases of swine influenza
Centers for Disease Control
CDC Director’s Update Brief July 21, 2009
– novel 2009-H1N1 Declarations
• WHO: Pandemic Phase 6(11 JUN 2009 1600 EDT)
• USG: Public Health Emergency declared (26 Apr 2009)
• HHS: Downgraded to Phase 1 Awareness (9 May 2009)
Only hospitalizations and deaths of cases will be reported as of 23 July 2009.
Centers for Disease Control
CDC Director’s H1N1 Update Brief July 17, 2009
Novel 2009-H1 N1 Declarations
* WHO: Pandemic Phase 6(11 JUN 2009 1600 EDT)
* Outbreaks in at least one country in > two WHO regions
* USG: Public Health Emergency declared (26 Apr 2009)
* HHS: Downgraded to Phase 1 Awareness (9 May 2009)